FOR IMMEDIATE RELEASE
TORONTO, ON – January 29, 2014 – SCiAN Services, Inc., a North American Clinical Data Management – Biostatistics CRO and EDC solution provider announces that Angiochem, a clinical-stage biotechnology company has selected SCiAN as its preferred provider for data management, biostatistics and eClinical systems starting with its upcoming studies. The agreement converts SCiAN’s previous ad hoc relationship with Angiochem, to one in which SCiAN will support its customer with data management and biostatistics through its advanced eClinical platform, EDCpro.
“We value our partnership with Angiochem,” said Ms. St. Clare Chung, Director of Biostatistics & CDM, at SCiAN Services. “Key to this clinical development collaboration is our ability to extend preferred pricing to Angiochem, which results from greater efficiencies accrued through multiple trials run on the same eClinical platform, EDCpro.”
“Biotech drug developers are increasingly looking for ways to conserve resources,” said Dr. Miklos Schulz, President and CEO of SCiAN Services. “Preferred vendor partnerships offer up the opportunity for bottom-line savings, while locking in available expertise and achieving the benefit of long-term knowledge growth in their clinical development programs, representing an even greater return on the initial cost saving.”
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB. Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.
SCiAN Services is a North American leading Clinical Data Management – Biostatistics – Pharmacovigilance CRO and EDC solution provider. Drug developers (Biotech/Biopharma, and pharmaceutical companies) rely on SCiAN’s 27 years of experience in IND stage clinical trials phases I-III. SCiAN’s therapeutic area expertise developed in over 650 clinical trials includes oncology, CNS, infectious diseases, inflammatory / autoimmune diseases, diabetes, etc. The company’s service depth is further backed by its industry renowned EDCpro platform, custom developed for small to medium size drug development companies and their CROs.
For more information, please contact:
SCiAN Services, Inc.
Toronto, ON Canada M9P 3V4
Ph: 416 231 8008
Fx: 416 231 1422
SCiAN Services USA, Inc.
King of Prussia, PA 19406
SCiAN Services USA, Inc.
Walnut Creek, CA 94597
Toll-free (U.S. & Canada): 1 800 915 9315